# Octreotide Efficacy and Safety in First-line Acromegalic Patients

> **NCT00171886** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 20 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** Octreotide

## Key facts

- **NCT ID:** NCT00171886
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** 2006-05
- **Final completion:** 2006-05
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00171886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00171886, "Octreotide Efficacy and Safety in First-line Acromegalic Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00171886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*